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OxLDL is recognized by macrophage scavenger receptors, including CD36; we have recently found that Platelet-Activating Factor
Receptor (PAFR) is also involved. Since PAFR in macrophages is associated with suppressor function, we examined the effect of
oxLDL onmacrophage phenotype. It was found that the presence of oxLDLduringmacrophage differentiation induced highmRNA
levels to IL-10, mannose receptor, PPAR𝛾 and arginase-1 and low levels of IL-12 and iNOS.When human THP-1 macrophages were
pre-treated with oxLDL then stimulated with LPS, the production of IL-10 and TGF-𝛽 significantly increased, whereas that of IL-
6 and IL-8 decreased. In murine TG-elicited macrophages, this protocol significantly reduced NO, iNOS and COX2 expression.
Thus, oxLDL induced macrophage differentiation and activation towards the alternatively activated M2-phenotype. In murine
macrophages, oxLDL induced TGF-𝛽, arginase-1 and IL-10 mRNA expression, which were significantly reduced by pre-treatment
with PAFR antagonists (WEB and CV) or with antibodies to CD36. The mRNA expression of IL-12, RANTES and CXCL2 were
not affected. We showed that this profile of macrophage activation is dependent on the engagement of both CD36 and PAFR. We
conclude that oxLDL induces alternative macrophage activation by mechanisms involving CD36 and PAFR.
1. Introduction
The stimulation of monocytes/macrophages by modified low
density lipoprotein (LDL), such as oxidized LDL (oxLDL),
is an early event in atherosclerosis development. These
macrophages accumulate in the subendothelial space and
differentiate into foam cells [1], which contribute to a chronic
inflammatory response in the arterial wall and atherosclerotic
plaque progression [2]. Several pattern recognition receptors
are involved in oxLDL recognition by macrophages; CD36 is
one of the most studied.
Macrophages can acquire distinct phenotypes according
to stimuli from the microenvironment. M1 or classically
activated macrophages are induced by Th1 cytokines and
exhibit high microbicidal activity and induce inflammation.
In contrast, M2 or alternatively activated macrophages are
induced by Th2 cytokines and contribute to the resolution
of inflammation and tissue remodeling [3]. The atheroscle-
rotic plaque provides a complex microenvironment for
macrophages, and both populations, M1 and M2, have been
found in human lesions [4]. It has been demonstrated thatM1
macrophages are predominant in regions prone to rupture,
while M2 macrophages are mostly detected in the adventitia
and in stable plaque areas [5]. However, it is not knownwhich
role macrophages with such opposing functions play in the
progression of atherosclerosis. M2macrophages express high
levels of CD36 and SR-A1 and are thus able to efficiently take
up oxLDL and are more prone to differentiating into foam
cells [6]. Macrophages also express receptors for platelet-
activating factor (PAFR), and our previous work suggested
that PAFR works in conjunction with CD36 for optimal
oxLDL uptake and cytokine gene expression [7]. Moreover,
preferential production of IL-10 over IL-12 was observed
(submitted article).
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In the present study, we investigated the effect of oxLDL
on macrophage differentiation, activation, and phenotype
and the role played byCD36 and PAFR.We found that oxLDL
increases the expression of alternative activationmarkers and
that both CD36 and PAFR are involved.
2. Methods
2.1. Purification and Oxidation of LDL. The study was
approved by the ethics committee of the Institute of Bi-
omedical Sciences, University of Sa˜o Paulo. Plasma was
obtained from normolipidemic volunteers and treated with
benzamidine (2mM), gentamicin (0.5%), chloramphenicol
(0.25%), phenyl-methyl-sulfonyl-fluoride (PMSF) (0.5mM),
and aprotinin (0.1 units/mL). LDL (1.019–1.063 g/mL) was
isolated by sequential ultracentrifugation at 100,000 g at 4∘C,
using a P90AT-0132 rotor (CP70MX ultracentrifuge; Hitachi
Koki Co., Ltd., Tokyo, Japan). LDLwas dialyzed at 4∘C against
PBS (pH 7.4) with 1mMEDTA, filtered (0.22𝜇m), and stored
at 4∘C.Theprotein concentrationwas determined by theBCA
kit (Pierce, USA). Oxidized LDL (oxLDL) was obtained by
incubation of LDL (2mg/mL) with 20𝜇M CuSO
4
for 18 h at
37∘C. The oxidation of both protocols was terminated by the
addition of 0.5mM EDTA.
2.2. Human THP-1 Monocytic Cells. The monocytic line
THP-1 was cultured in RPMI-1640 medium supplemented
with 5% (v/v) fetal bovine serum (FBS), 100U/mL peni-
cillin, 100 𝜇g/mL streptomycin, 2mM L-glutamine, 15mM
HEPES, and 11mM sodium bicarbonate. Cell cultures were
maintained in a humidified atmosphere containing 5%
CO
2
at 37∘C. The differentiation of THP-1 monocytes into
macrophages was induced by 150 nM phorbol 12-myristate-
13-acetate (PMA) for 24 h. Nonadherent cells were removed
by aspiration of the supernatant followed by replacementwith
freshmedium.The experiments proceeded for 24 h according
to the protocol.
2.3. Culture of Murine Macrophages. Male C57Bl/6 7–10
weeks old mice were acquired from the Department of
Immunology Animal Facility at the University of Sa˜o Paulo
and kept in microisolator cages under specific pathogen-
free conditions. Animal care and research protocols were in
accordance with the principles and guidelines adopted by
the Brazilian College of Animal Experimentation (COBEA)
and approved by the Biomedical Sciences Institute/USP-
Ethical Committee for Animal Research (CEEA). Peritoneal
exudate cells were obtained by lavage of the peritoneal cavity
4 days after injection of 1mL of 3% thioglycolate medium.
The fluid lavage was centrifuged (100×g, 10min, 4∘C). The
cellular concentration was adjusted to 2 × 106 cells/mL with
RPMI 1640 medium, supplemented with 5% FCS, strep-
tomycin (100 𝜇g/mL), penicillin (60U/mL), sodium bicar-
bonate (11mM), l-glutamine (2mM), and HEPES (20mM),
referred to hereafter as RPMI/FBS. Cells were left to adhere
on microplates for 2 h at 37∘C in a 5% CO
2
. Nonadherent
cells were removed by aspiration of the supernatant and
replacement with fresh medium.The experiments proceeded
according to the protocol.
Bone marrow-derived macrophages (BMDM) were
obtained as previously described by Davies and Gordon [8],
with minor modifications. In brief, femurs were flushed with
DMEM medium containing 2mM L-glutamine, 100U/mL
penicillin G, and 100mg/mL streptomycin (all from Gibco,
Long Island, NY, USA), using a 26G × 1/2󸀠󸀠 needle. Cells were
grown in DMEM containing 20% L-929 cell-conditioned
medium (LCM) and 15% heat-inactivated fetal calf serum
(FCS), incubated at 37∘C in 5% CO
2
. On day 3, fresh DMEM
with LCM was added. A monolayer of macrophages was
scrapped on day 6 (96% of the cells were positive for CD11b
and F4/80). Macrophages were cultured in DMEM with 5%
FCS for one day before further experiments.
2.4. Quantification of Nitric Oxide. NO production was
assessed by nitrite production in culture supernatants using
the Griess reaction. Briefly, culture supernatants were incu-
bated with the Griess reagent (0.1% naphthylethylenediamine
dihydrochloride and 1% sulfanilamide in 2.5% phosphoric
acid, v/v) at room temperature for 10min. Absorbance was
determined using a Dinatech microplate reader at 540 nm. A
standard curve of sodium nitrite was used to determine the
concentration.
2.5. Western Blot for iNOS and COX-2 Expression. Thio-
glycolate-elicited macrophages were treated with different
concentrations of LDL or oxLDL for 24 h and then stimulated
with LPS (1𝜇g/mL). Cells were washed with cold PBS, and
lysates were obtained in lysis buffer (10% Nonidet P-40,
150mM NaCl, 10mM Tris-HCl, pH 7.6, and 2mM 0.1%
SDS) supplementedwith a protease inhibitor cocktail (Sigma-
Aldrich, Saint Louis, MO, USA) and phosphatase inhibitors
(10mM sodium fluoride and 1mM sodium orthovanadate).
Protein concentrations were determined using the Pierce
BCA Protein Assay Kit (Thermo Scientific, Rockford, IL,
USA). Equal amounts of proteins were separated by 10% SDS-
PAGE, transferred to a Hybond nitrocellulose membrane
(GE Healthcare, NJ, USA), and incubated with rabbit-anti-
COX-2 or rabbit-anti-iNOS (both from Cayman Chemical,
Ann Arbor, MI, USA), and with mouse anti-𝛽-actin (Sigma-
Aldrich, Saint Louis, MO, USA). As secondary antibodies,
we used antirabbit IgG-HPR (1 : 2000) and antimouse-HRP
(1 : 2000) (Cell Signaling Technology, Beverly, MA, USA).
Expression was visualized using SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific, Rockford,
IL, USA). The resulting autoradiograms were analyzed with
the AlphaEaseFC software V3.2 beta (Alpha Innotech, San
Leandro, CA, USA).
2.6. MTT Assay. The mitochondrial-dependent reduction
of methylthiazolyldiphenyl-tetrazolium bromide (MTT) into
insoluble formazan crystals was used to evaluate cell viability.
Briefly, 500mg/mL of MTT in RPMI was added to the cells
after treatment. Cells were incubated for 3 h at 37∘C in a
5% CO
2
atmosphere. Next, a solution of 10% SDS in 0.01M
HCl was added to the cells to dissolve the crystals, and
the absorbance was measured after 14 h using a Dynatech
microplate reader at 570 nm.
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2.7. Real-Time RT-PCR. Cells were harvested at various
time points, and total RNA was isolated using the Trizol
reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. cDNA was generated from total
RNA using the RevertAid First Strand cDNA Synthesis Kit
(Thermo Scientific Fermentas, Vilnius, Lithuania). Real-time
PCR was performed with the Stratagene MxPro3005PTM
QPCR Systems (Santa Clara, CA, USA), using SYBR Green
(SYBR Green Master Mix, Applied Biosystems, Warrington,
UK) and specific primers for IL-10,MR, Arg-1, PPAR-𝛾, iNOS,
IL-12p40, TGF-𝛽1, RANTES, and GAPDH (Table 1). Relative
gene expression was calculated by the 2−ΔΔCT method as
previously described [9]. Data are shown as the fold change
in expression of the target gene relative to the internal control
gene (GAPDH).
2.8. Detection of Cytokines. Human IL-6, IL-8, IL-10, TGF-𝛽,
IL-1𝛽, and TNF-𝛼 andmurine IL-10 and IL-12p40 production
were determined by ELISA (ELISA Kits, BD Biosciences, San
Diego, CA, USA) according to the manufacturer’s specifica-
tions.
3. Results and Discussion
3.1. oxLDL Preferentially Increases LPS-Induced Anti-Inflam-
matory Cytokines. Oxidized LDL was obtained according
to a previous publication and presented high values for
both negative charge and TBARS compared to non-modified
LDL [10]. Human monocytic THP-1 cells were differentiated
into macrophages using PMA, followed by treatment with
oxLDL (20𝜇g/mL); 24 h later, they were stimulated with LPS
(100 ng/mL) for an additional 24 h. We found that pretreat-
ment with oxLDL decreased the LPS-induced production of
IL-8 and IL-6 (29% and 34% inhibition, resp.), potentiated
the production of IL-10 (2-fold increase) and TGF-𝛽 (3-fold
increase), and did not significantly affect TNF-𝛼 and IL-1𝛽
production (Figure 1). Although pretreatment with oxLDL
did not significantly affect the LPS-induced production of
TNF𝛼 and IL-1𝛽, the fact that it decreased IL-6 and IL-8 and
increased IL-10 and TGF-𝛽 production suggests that oxLDL
stimulates macrophages towards an alternative activation
phenotype.
It is known that depending on the degree of LDL oxi-
dation, different products are formed, and distinct biological
effects have been attributed to the LDLpreparations subjected
to high and low oxidation [11–13]. Here, we used oxLDL
with high oxidative degree. In this situation, phospholipids,
triacylglycerol, and cholesterol esters are transformed into
hydroperoxides which react with ApoB-100, resulting in
modification and fragmentation of amino acid side chains
[14, 15].
3.2. oxLDL Inhibits LPS-Induced NO, iNOS, and COX-2.
We next examined the effect of oxLDL on thioglycolate-
elicited murine macrophages that already express a pro-
inflammatory phenotype.Macrophageswere treatedwith dif-
ferent concentrations of oxLDL for 24 h and then stimulated
with LPS (1𝜇g/mL) for an additional 24 h. Figure 2(a) shows
that oxLDL inhibits nitric oxide (NO) production induced
by LPS in a dose-dependent manner. No effect was observed
when nonoxidized LDL was used. Treatment with oxLDL
also inhibited the expression of iNOS and COX-2 induced
by LPS stimulation (52% and 55% for iNOS and COX-2,
resp.) (Figures 2(b) and 2(c)).The inhibitory effects of oxLDL
were not related to a decrease in cell viability, evaluated
by measuring mitochondrial activity by the MTT assay,
which was actually increased in oxLDL-treated macrophages
(Figure 2(d)).
Although oxLDL particles have been associated with
proinflammatory mechanisms related to the development of
atherosclerosis [2], our data indicate that oxLDL increases
anti-inflammatory and reduces pro-inflammatory markers
induced by LPS, favoring macrophage differentiation toward
the M2 phenotype. Compounds present in the oxLDL
particle, such as sphingosine 1-phosphate (S1P) and oxidized
1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
(oxPAPC) have been shown to inhibit TLR2 and TLR4
activation, respectively [16, 17]. The complexity involved in
this mechanism could be explained by interactions between
different compounds formed after the oxidative process with
different receptors present on macrophages.
3.3.The Presence of oxLDL during Macrophage Differentiation
Induces the M2 Phenotype. Murine bone marrow-derived
cells were differentiated to macrophages (BMDM) with L929
supernatant for six days in the presence of oxLDL. Cells were
treated with oxLDL (20𝜇g/mL) on the first day of culture and
supplemented every two days. We found that macrophages
treated with oxLDL expressed high levels of mRNA for the
M2 macrophage markers IL-10, arginase-1 (Arg-1), mannose
receptor (MR), and PPAR𝛾 and decreased expression of IL-
12 mRNA with no effect on iNOS mRNA (Figure 3). This
indicates that the presence of oxLDL during macrophage
differentiation shifts the phenotype toward the M2 profile.
3.4. Engagement of PAFR andCD36 is Required for the oxLDL-
Induced M2 Phenotype. In a previous study, we found that
costimulation of PAFR and CD36 is needed for optimal
macrophage activation induced by oxLDL [7]. Here, we
investigated if both receptors are involved in the induction of
the M2 phenotype. Murine BMDM were treated with PAFR
antagonists (WEB2086 or CV3988) alone or in combination
with blocking antibody to CD36 for 30min and then treated
with oxLDL (20𝜇g/mL) for 5 h. Figure 4(a) shows that oxLDL
induced the expression of TGF-𝛽 and Arg-1 mRNA and that
this was reversed by treatment with PAFR antagonists (TGF-
𝛽: 36% and 45% inhibition; Arg1: 57% and 50% inhibition
for WEB and CV, resp.). Blockage of CD36 reduced only the
mRNA expression of TGF-𝛽 (56%). Simultaneous blockage
of CD36 and PAFR did not further reduce Arg-1 and TGF-𝛽
mRNA expression.The oxLDL also induced the expression of
RANTES and CXCL2, but this was not affected by treatment
with the PAFR antagonists or CD36 blocking antibody. Next,
we examined the requirement of PAFR and CD36 for IL-10
and IL-12 production. To ensure the production of detectable
levels of these cytokines, the cells were activated with LPS.
BMDM were pretreated with the CD36 blocking antibody
alone, or in combination with the PAFR antagonists 30min
4 Mediators of Inflammation
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Figure 1: oxLDL preferentially increases LPS-induced anti-inflammatory cytokines. THP-1 monocytes were differentiated into macrophages
with PMA, followed by treatment with oxLDL (20𝜇g/mL) for 24 h, and then stimulated with LPS (100 ng/mL) for an additional 24 h.
Cytokines concentration in the supernatant was measured by ELISA. Data are presented as mean ± SEM of four independent experiments.
∗
𝑃 < 0.05 versus LPS-stimulated cells.
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Figure 2: oxLDL treatment inhibits LPS-induced NO, iNOS, and COX-2. Thioglycolate-elicited murine macrophages were treated with
different concentrations of LDL or oxLDL for 24 h and then stimulated with LPS (1𝜇g/mL) for an additional 24 h. (a) Nitric oxide production
was analyzed by the Griess assay. (b) iNOS and COX-2 expressions were analyzed by western blot, and the protein expression was quantified
by AlphaEase FC software, V3.2 beta (Alpha Innotech). The autoradiographs show one representative experiment, ∗𝑃 < 0.05 versus LPS
stimulated cells. (c) Cell viability was measured by MTT assay, ∗𝑃 < 0.05 comparing oxLDL-treated with the nontreated cells. Data are
presented as mean ± SEM of six independent experiments.
before overnight stimulation with oxLDL (20𝜇g/mL) fol-
lowed by activation with LPS (10 ng/mL). Figure 4(b) shows
that oxLDL increased the LPS-induced production of IL-10
but did not affect IL-12. Furthermore, the IL-10 concentration
was strongly reduced by the PAFR antagonists WEB and CV
and by the CD36 blocking antibody.
Our results show that both CD36 and PAFR are involved
in IL-10 production. Although several receptors may be
involved in oxLDL recognition [18], the upregulation of IL-
10 induced by oxLDL depends mainly on CD36 and PAFR
since, in the present study, the production of this cytokine
was almost completely blocked by treatment with PAFR
antagonists and antibodies to CD36. It has been described
that oxLDL induces Arginase expression and activity in
macrophages and in endothelial cells [19, 20]. We showed
here that PAFR antagonists decreased Arg-1 and TGF-𝛽1
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Figure 3: oxLDL induces macrophages differentiation towards M2 phenotype. Murine bone marrow-derived cells were differentiated to
macrophages (BMDM) with L929 supernatant for six days in the presence of oxLDL. Cells were treated with oxLDL (20𝜇g/mL) on the first
day of culture and supplemented every two days. The mRNA expression of IL-10, arginase-1 (Arg-1), mannose receptor (MR), PPAR𝛾, IL-
12p40, and iNOSwas assessed by real-time PCR.Data are presented asmean± SEMof independent experiments and expressed in fold change.
∗
𝑃 < 0.05 comparing oxLDL-treated with nontreated cells.
Table 1: List of primer sequences used for real-time RT-PCR analysis in this study.
Name Forward Reverse
IL-10 5󸀠-CAGAGCCACATGCTCCTAGA-3󸀠 5󸀠-TGTCCAGCTGGTCCTTTGTT-3󸀠
MR 5󸀠-GATATGAAGCCATGTACTCCTTACTGG-3󸀠 5󸀠-GGCAGAGGTGCAGTCTGCAT-3󸀠
Arg-1 5󸀠-TTCTCAAAAGGACAGCCTCG-3󸀠 5󸀠-AGCTCTTCATTGGCTTTCCC-3󸀠
PPAR-𝛾 5󸀠-TCCTGTAAAAGCCCGGAGTAT-3󸀠 5󸀠-GCTCTGGTAGGGGCAGTGA-3󸀠
iNOS 5󸀠-GTTCTCAGGCCAACAATACAAGA-3󸀠 5󸀠-GTGGACGGGTCGATGTCAC-3󸀠
IL-12p40 5󸀠-TGGTTTGCCATCGTTTTGCTG-3󸀠 5󸀠-ACAGGTGAGGTTCACTGTTTCT-3󸀠
TGF-𝛽1 5󸀠-TGGAGCAACATGTGGAACTC-3󸀠 5󸀠-CAGCAGCCGGTTACCAAG-3󸀠
RANTES 5󸀠-TTTGCCTACCTCTCCCTCG-3󸀠 5󸀠-CGACTGCAAGATTGGAGCACT-3󸀠
CXCL2 5󸀠-CGCCCAGACAGAAGTCATAGCC-3󸀠 5󸀠-TCTTCCGTTGAGGGACAGCAGC-3󸀠
GAPDH 5󸀠-AGGTCGGTGTGAACGGATTTG-3󸀠 5󸀠-TGTAGACCATGTAGTTGAGGTCA-3󸀠
mRNA expression induced by oxLDL, indicating that PAFR
activation is required for the induction of alternative acti-
vation markers in macrophages. Atherosclerosis is charac-
terized by a chronic inflammatory reaction in the arterial
wall, and both forms of activated macrophages, classical and
alternative, have been found in atherosclerotic lesions [4]. M1
macrophages are mostly present in areas prone to rupture,
while M2 macrophages are found in the adventitia, and both
M1 and M2 are present in the fibrous cap [5]. However,
the real function of each macrophage population still needs
to be elucidated. In the atherosclerotic plaque, there are
different forms of modified LDL. Here, we found that LDL
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Figure 4: Engagement of PAFR and CD36 is required for the oxLDL-induced M2 phenotype. Murine BMDM were pretreated with PAFR
antagonists WEB2086 (50𝜇M) or CV3988 (10𝜇M) alone or in combination with blocker antibody to CD36 (1 : 500) for 30min and then
treated with oxLDL (20𝜇g/mL). (a) The mRNA expression of TGF-𝛽, Arg-1, RANTES and CXCL2 was analyzed by real-time PCR after 5 h.
(b) BMDM were treated overnight with oxLDL and then stimulated with LPS (10 ng/mL). IL-10 and IL-12 production was assessed in the
supernatants by ELISA assays. ∗𝑃 < 0.05 comparing oxLDL-treated with nontreated cells and #𝑃 < 0.05 versus oxLDL-treated cells.
with a high degree of oxidation increased anti-inflammatory
markers in a PAFR- and CD36-dependent manner. We do
not exclude the idea that additional mechanisms may con-
tribute to oxLDL-induced macrophage differentiation into
the M1 or M2 phenotype. It can be speculated that the
presence of M2 macrophages in the plaque is an attempt
of the organism to control the inflammatory response; in
this case, the PAFR would be involved in atheroprotection.
However, M2 macrophages express more CD36 [4, 6] and
are more likely to become foam cells, which contribute to the
8 Mediators of Inflammation
pathophysiology of atherosclerosis [21]. Moreover, these cells
are more sensitive to death in a high lipid environment, such
as the lipid core of the atherosclerotic plaque [6].
4. Conclusions
In the present study, we demonstrated that oxLDL induces
macrophage differentiation towards an alternative phenotype
and that this requires the engagement of PAFR and CD36.
As the real function of M2 macrophages in the development
of atherosclerosis remains unclear, in vivo studies using
PAFR antagonists are needed before suggesting their use as
a therapeutic approach for the treatment of atherosclerosis.
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